Peroxitech is an innovative biopharmaceutical company dedicated to developing a novel peptide aimed at treating acute lung injury. The company’s research is grounded in the discovery of a new signaling pathway that plays a crucial role in the oxidative injury cascade, which is significant in the context of lung health. This breakthrough science positions Peroxitech at the forefront of addressing acute lung injuries, potentially leading to new therapeutic options that can save and improve lives.

The team behind Peroxitech comprises experienced professionals with extensive backgrounds in medicine and molecular biology. Co-founder Dr. Aron Fisher, a professor and director at the Institute for Environmental Medicine at the University of Pennsylvania, specializes in acute lung injury and is a co-inventor of the technology. Alongside him, Dr. Sheldon I. Feinstein, also a co-founder, has over three decades of research experience in lung molecular biology. The leadership of Thomas Han, the CEO and co-founder, further strengthens the company with his 30 years of expertise in pharmaceuticals, focusing on operations and commercialization strategies. Together, this team is committed to advancing Peroxitech's mission of developing effective treatments for acute lung conditions.

United States

Peroxitech is a privately held emerging biopharmaceutical company focused on the development and commercialization of a novel peptide for treating acute lung injury (ALI). The company has secured seed financing and Series A financing to advance its treatment for ALI, and has been awarded an NIH grant to develop a novel therapeutic approach to expand and improve the lung transplant organ pool.

Peroxitech

Company Details